9. REFERENCES
1.Boorjian, S.A., et al. Risk factors and outcomes of urethral recurrence following radical cystectomy. Eur Urol, 2011. 60: 1266.
https://www.ncbi.nlm.nih.gov/pubmed/21871713
2.Witjes, J.A., Bruins, H.M., Carrion Puig, A., Cathomas, R, et al members of the EAU Guidelines Panel on Muscle-invasive and Metastatic Bladder Cancer., EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Edn. presented at the 38th EAU Annual Congress Milan, in EAU Guidelines 2023: Arnhem. The Netherlands.
https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
3.Gakis, G., et al. European Association of Urology Guidelines on Primary Urethral Carcinoma-2020 Update. Eur Urol Oncol, 2020. 3: 424.
https://www.ncbi.nlm.nih.gov/pubmed/32605889
4.Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009.
https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidencemarch-2009/
5.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://pubmed.ncbi.nlm.nih.gov/18467413
6.Gatta, G., et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer, 2011. 47: 2493.
https://pubmed.ncbi.nlm.nih.gov/22033323
7.Brierley, J.D., et al., TNM classification of malignant tumors. UICC International Union Against Cancer. 2017, Wiley/Blackwell. p. 208.
https://www.wiley.com/en-gb/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-p-9781119263579
8.RARECARENet. Surveillance of Rare Cancers in Europe. 2019. Access date Dec 2022.
http://www.rarecare.eu/default.asp
9.Wenzel, M., et al. Incidence rates and contemporary trends in primary urethral cancer. Cancer Causes Control, 2021. 32: 627.
https://www.ncbi.nlm.nih.gov/pubmed/33751293
10.Wenzel, M., et al. Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. Clin Genitourin Cancer, 2021. 19: 135.
https://www.ncbi.nlm.nih.gov/pubmed/33526327
11.Krukowski, J., et al. Primary urethral carcinoma - unexpected cause of urethral stricture. Case report and review of the literature. Med Ultrason, 2019. 21: 494.
https://www.ncbi.nlm.nih.gov/pubmed/31765461
12.Guo, H., et al. Lichen Sclerosus Accompanied by Urethral Squamous Cell Carcinoma: A Retrospective Study From a Urethral Referral Center. Am J Mens Health, 2018. 12: 1692.
https://www.ncbi.nlm.nih.gov/pubmed/29926751
13.Colapinto, V., et al. Primary carcinoma of the male urethra developing after urethroplasty for stricture. J Urol, 1977. 118: 581.
https://www.ncbi.nlm.nih.gov/pubmed/916053
14.Mohanty, N.K., et al. Squamous cell carcinoma of perineal urethrostomy. Urol Int, 1995. 55: 118.
https://www.ncbi.nlm.nih.gov/pubmed/8533195
15.Sawczuk, I., et al. Post urethroplasty squamous cell carcinoma. N Y State J Med, 1986. 86: 261.
https://www.ncbi.nlm.nih.gov/pubmed/3459083
16.Mohan, H., et al. Squamous cell carcinoma of the prostate. Int J Urol, 2003. 10: 114.
https://www.ncbi.nlm.nih.gov/pubmed/12588611
17.Arva, N.C., et al. Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature. Diagn Pathol, 2011. 6: 46.
https://www.ncbi.nlm.nih.gov/pubmed/21627811
18.Cupp, M.R., et al. Detection of human papillomavirus DNA in primary squamous cell carcinoma of the male urethra. Urology, 1996. 48: 551.
https://www.ncbi.nlm.nih.gov/pubmed/8886059
19.Wiener, J.S., et al. Oncogenic human papillomavirus type 16 is associated with squamous cell cancer of the male urethra. Cancer Res, 1992. 52: 5018.
https://www.ncbi.nlm.nih.gov/pubmed/1325290
20.Ahmed, K., et al. Urethral diverticular carcinoma: an overview of current trends in diagnosis and management. Int Urol Nephrol, 2010. 42: 331.
https://www.ncbi.nlm.nih.gov/pubmed/19649767
21.Chung, D.E., et al. Urethral diverticula in women: discrepancies between magnetic resonance imaging and surgical findings. J Urol, 2010. 183: 2265.
https://www.ncbi.nlm.nih.gov/pubmed/20400161
22.Thomas, A.A., et al. Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations. J Urol, 2008. 180: 2463.
https://www.ncbi.nlm.nih.gov/pubmed/18930487
23.Libby, B., et al. Non-surgical treatment of primary female urethral cancer. Rare Tumors, 2010. 2: e55.
https://www.ncbi.nlm.nih.gov/pubmed/21139970
24.Altman, D., et al. Cancer Risk After Midurethral Sling Surgery Using Polypropylene Mesh. Obstet Gynecol, 2018. 131: 469.
https://www.ncbi.nlm.nih.gov/pubmed/29420401
25.Gandhi, J.S., et al. Clear cell adenocarcinoma of the male urethral tract. Indian J Pathol Microbiol, 2012. 55: 245.
https://www.ncbi.nlm.nih.gov/pubmed/22771656
26.Mehra, R., et al. Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. Am J Pathol, 2014. 184: 584.
https://www.ncbi.nlm.nih.gov/pubmed/24389164
27.Visser, O., et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer, 2012. 48: 456.
https://pubmed.ncbi.nlm.nih.gov/22119351
28.Rabbani, F. Prognostic factors in male urethral cancer. Cancer, 2011. 117: 2426.
https://www.ncbi.nlm.nih.gov/pubmed/24048790
29.Aleksic, I., et al. Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival. Urol Ann, 2018. 10: 170.
https://www.ncbi.nlm.nih.gov/pubmed/29719329
30.Sui, W., et al. Outcomes and Prognostic Factors of Primary Urethral Cancer. Urology, 2017. 100: 180.
https://www.ncbi.nlm.nih.gov/pubmed/27720774
31.Wenzel, M., et al. Epidemiology of Unconventional Histological Subtypes of Urethral Cancer. Urol Int, 2023. 107: 15.
https://www.ncbi.nlm.nih.gov/pubmed/35882213
32.Greiman, A.K., et al. Urethral diverticulum: A systematic review. Arab J Urol, 2019. 17: 49.
https://www.ncbi.nlm.nih.gov/pubmed/31258943
33.Board, W.C.o.T.E., WHO Classification of Tumours, Urinary and Male Genital Tumours. Vol. 5th Edn, Volume 8. 2022.
34.Shanks, J.H., et al. Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2019. 75: 453.
https://www.ncbi.nlm.nih.gov/pubmed/31009090
35.Gheiler, E.L., et al. Management of primary urethral cancer. Urology, 1998. 52: 487.
https://www.ncbi.nlm.nih.gov/pubmed/9730466
36.Karnes, R.J., et al. Surgery for urethral cancer. Urol Clin North Am, 2010. 37: 445.
https://www.ncbi.nlm.nih.gov/pubmed/20674699
37.Blaivas, J.G., et al. Periurethral masses: etiology and diagnosis in a large series of women. Obstet Gynecol, 2004. 103: 842.
https://www.ncbi.nlm.nih.gov/pubmed/15121554
38.Wojcik, E.M., Kurtycz, D.F.J., Rosenthal, D.L. , The Paris System for Reporting Urinary Cytology. 2022, Switzerland.
https://link.springer.com/book/10.1007/978-3-030-88686-8
39.Touijer, A.K., et al. Role of voided urine cytology in diagnosing primary urethral carcinoma. Urology, 2004. 63: 33.
https://www.ncbi.nlm.nih.gov/pubmed/14751342
40.Gakis, G., et al. Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma. Urol Int, 2016. 97: 134.
https://www.ncbi.nlm.nih.gov/pubmed/27462702
41.Samm, B.J., et al. Penectomy: a technique to reduce blood loss. Urology, 1999. 53: 393.
https://www.ncbi.nlm.nih.gov/pubmed/9933061
42.Donat, S.M., et al. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol, 2001. 165: 1580.
https://www.ncbi.nlm.nih.gov/pubmed/11342921
43.Schubert*, T., et al. MP11-20 THE PREDICTIVE ACCURACY BETWEEN CLINICAL STAGING AND PATHOLOGICAL STAGING IN PATIENTS WITH PRIMARY URETHRAL CARCINOMA. Journal of Urology, 2019. 201: e135.
https://www.auajournals.org/doi/abs/10.1097/01.JU.0000555184.87550.3c
44.Del Gaizo, A., et al. Magnetic resonance imaging of solid urethral and peri-urethral lesions. Insights Imaging, 2013. 4: 461.
https://www.ncbi.nlm.nih.gov/pubmed/23686749
45.Itani, M., et al. MRI of female urethra and periurethral pathologies. Int Urogynecol J, 2016. 27: 195.
https://www.ncbi.nlm.nih.gov/pubmed/26209954
46.Stewart, S.B., et al. Imaging tumors of the penis and urethra. Urol Clin North Am, 2010. 37: 353.
https://www.ncbi.nlm.nih.gov/pubmed/20674692
47.Kim, B., et al. Imaging of the male urethra. Semin Ultrasound CT MR, 2007. 28: 258.
https://www.ncbi.nlm.nih.gov/pubmed/17874650
48.Raman, S.P., et al. Upper and Lower Tract Urothelial Imaging Using Computed Tomography Urography. Radiol Clin North Am, 2017. 55: 225.
https://www.ncbi.nlm.nih.gov/pubmed/28126213
49.Gourtsoyianni, S., et al. MRI at the completion of chemoradiotherapy can accurately evaluate the extent of disease in women with advanced urethral carcinoma undergoing anterior pelvic exenteration. Clin Radiol, 2011. 66: 1072.
https://www.ncbi.nlm.nih.gov/pubmed/21839430
50.Laudicella, R., et al. (18)F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma. Nucl Med Mol Imaging, 2019. 53: 296.
https://www.ncbi.nlm.nih.gov/pubmed/31456863
51.Dayyani, F., et al. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol, 2013. 31: 1171.
https://www.ncbi.nlm.nih.gov/pubmed/22534087
52.Gakis, G., et al. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World J Urol, 2016. 34: 97.
https://www.ncbi.nlm.nih.gov/pubmed/25981402
53.Werntz, R.P., et al. The role of inguinal lymph node dissection in men with urethral squamous cell carcinoma. Urol Oncol, 2018. 36: 526 e1.
https://www.ncbi.nlm.nih.gov/pubmed/30446445
54.Naumann, C.M., et al. Reliability of dynamic sentinel node biopsy combined with ultrasound-guided removal of sonographically suspicious lymph nodes as a diagnostic approach in patients with penile cancer with palpable inguinal lymph nodes. Urol Oncol, 2015. 33: 389.e9.
https://pubmed.ncbi.nlm.nih.gov/25934562
55.Carroll, P.R., et al. Surgical anatomy of the male and female urethra. Urol Clin North Am, 1992. 19: 339.
https://www.ncbi.nlm.nih.gov/pubmed/1574824
56.Sharp, D., et al., Surgery of penile and urethral carcinoma, in Campbell’s Urology, D. McDougal, A. Wein, L. Kavoussi, A. Novick, A. Partin, C. Peters & P. Ramchandani, Editors. 212, Saunders Elsevier: Philadelphia, PA, USA.
57.Abudurexiti, M., et al. Prognosis of rare pathological primary urethral carcinoma. Cancer Manag Res, 2018. 10: 6815.
https://www.ncbi.nlm.nih.gov/pubmed/30584373
58.Swartz, M.A., et al. Incidence of primary urethral carcinoma in the United States. Urology, 2006. 68: 1164.
https://www.ncbi.nlm.nih.gov/pubmed/17141838
59.Wu, J., et al. Primary tumor surgery improves survival in non-metastatic primary urethral carcinoma patients: a large population-based investigation. BMC Cancer, 2021. 21: 857.
https://www.ncbi.nlm.nih.gov/pubmed/34315433
60.Wenzel, M., et al. The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. Urol Oncol, 2021. 39: 369.e9.
https://pubmed.ncbi.nlm.nih.gov/33309509
61.Champ, C.E., et al. Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology, 2012. 80: 374.
https://www.ncbi.nlm.nih.gov/pubmed/22857759
62.Panettieri, V., et al. External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. Frontiers in Oncology, 2020. 10: 910.
https://pubmed.ncbi.nlm.nih.gov/32596153/
63.Derksen, J.W., et al. Primary urethral carcinoma in females: an epidemiologic study on demographical factors, histological types, tumour stage and survival. World J Urol, 2013. 31: 147.
https://www.ncbi.nlm.nih.gov/pubmed/22614443
64.Wenzel, M., et al. Comparison Between Urothelial and Non-Urothelial Urethral Cancer. Front Oncol, 2020. 10: 629692.
https://www.ncbi.nlm.nih.gov/pubmed/33585257
65.Stone, B.V., et al. The effect of centralization of care on overall survival in primary urethral cancer. Urologic Oncology: Seminars and Original Investigations, 2021. 39: 133.
https://pubmed.ncbi.nlm.nih.gov/33268273/
66.Gakis, G., et al. The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. Urol Oncol, 2018. 36: 10 e7.
https://www.ncbi.nlm.nih.gov/pubmed/29055518
67.Dalbagni, G., et al. Male urethral carcinoma: analysis of treatment outcome. Urology, 1999. 53: 1126.
https://www.ncbi.nlm.nih.gov/pubmed/10367840
68.Smith, Y., et al. Penile-preserving surgery for male distal urethral carcinoma. BJU Int, 2007. 100: 82.
https://www.ncbi.nlm.nih.gov/pubmed/17488307
69.Pedrosa, J.A., et al. Distal urethrectomy for localized penile squamous carcinoma in situ extending into the urethra: an updated series. Int Urol Nephrol, 2014. 46: 1551.
https://www.ncbi.nlm.nih.gov/pubmed/24633698
70.Kulkarni, M., et al. MP10-16 Substitution urethroplasty for treatment of distal urethral carcinoma and carcinoma in situ. J. Urol 193: e117.
http://dx.doi.org/10.1016/j.juro.2015.02.417
71.Torbrand, C., et al. Diagnosing Distal Urethral Carcinomas in Men Might Be Only the Tip of the Iceberg. Clin Genitourin Cancer, 2017. 15: e1131.
https://www.ncbi.nlm.nih.gov/pubmed/28784424
72.Dimarco, D.S., et al. Surgical treatment for local control of female urethral carcinoma. Urol Oncol, 2004. 22: 404.
https://www.ncbi.nlm.nih.gov/pubmed/15464921
73.DiMarco, D.S., et al. Outcome of surgical treatment for primary malignant melanoma of the female urethra. J Urol, 2004. 171: 765.
https://www.ncbi.nlm.nih.gov/pubmed/14713806
74.Garden, A.S., et al. Primary carcinoma of the female urethra. Results of radiation therapy. Cancer, 1993. 71: 3102.
https://www.ncbi.nlm.nih.gov/pubmed/8490839
75.Milosevic, M.F., et al. Urethral carcinoma in women: results of treatment with primary radiotherapy. Radiother Oncol, 2000. 56: 29.
https://www.ncbi.nlm.nih.gov/pubmed/10869752
76.Zinman, L.N., et al. Management of Proximal Primary Urethral Cancer: Should Multidisciplinary Therapy Be the Gold Standard? Urol Clin North Am, 2016. 43: 505.
https://www.ncbi.nlm.nih.gov/pubmed/27717436
77.Cahn, D.B., et al. Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. Urol Oncol, 2017. 35: 670 e15.
https://www.ncbi.nlm.nih.gov/pubmed/28803701
78.Dayyani, F., et al. Management of advanced primary urethral carcinomas. BJU Int, 2014. 114: 25.
https://www.ncbi.nlm.nih.gov/pubmed/24447439
79.Peyton, C.C., et al. Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. Clin Genitourin Cancer, 2018. 16: e1003.
https://www.ncbi.nlm.nih.gov/pubmed/29859736
80.Mano, R., et al. Primary urethral cancer: treatment patterns and associated outcomes. BJU Int, 2020. 126: 359.
https://www.ncbi.nlm.nih.gov/pubmed/32336001
81.Celtik, K., et al. Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database. Clin Genitourin Cancer, 2022. 20: 244.
https://www.ncbi.nlm.nih.gov/pubmed/35181268
82.Gakis, G., et al. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Ann Oncol, 2015. 26: 1754.
https://www.ncbi.nlm.nih.gov/pubmed/25969370
83.Kent, M., et al. Combined chemoradiation as primary treatment for invasive male urethral cancer. J Urol, 2015. 193: 532.
https://www.ncbi.nlm.nih.gov/pubmed/25088950
84.Gakis, G. Editorial Comment to Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. Int J Urol, 2014. 21: 424.
https://www.ncbi.nlm.nih.gov/pubmed/24251884
85.Itoh, J., et al. Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. Int J Urol, 2014. 21: 422.
https://www.ncbi.nlm.nih.gov/pubmed/24251859
86.Hara, I., et al. Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy. Int J Urol, 2004. 11: 678.
https://www.ncbi.nlm.nih.gov/pubmed/15285764
87.Cohen, M.S., et al. Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. J Urol, 2008. 179: 536.
https://www.ncbi.nlm.nih.gov/pubmed/18076921
88.Son, C.H., et al. Optimizing the Role of Surgery and Radiation Therapy in Urethral Cancer Based on Histology and Disease Extent. Int J Radiat Oncol Biol Phys, 2018. 102: 304.
https://www.ncbi.nlm.nih.gov/pubmed/29908944
89.Patschan, O., et al. Systematic Review of the Role of BCG in the Treatment of Urothelial Carcinoma of the Prostatic Urethra. Bladder Cancer, 2021. 7: 213.
https://content.iospress.com/download/bladder-cancer/blc201516?id=bladder-cancer%2Fblc201516
90.Njinou Ngninkeu, B., et al. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J Urol, 2003. 169: 149.
https://www.ncbi.nlm.nih.gov/pubmed/12478124
91.Hillyard, R.W., Jr., et al. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin. J Urol, 1988. 139: 290.
https://www.ncbi.nlm.nih.gov/pubmed/3339727
92.Solsona, E., et al. The prostate involvement as prognostic factor in patients with superficial bladder tumors. J Urol, 1995. 154: 1710.
https://www.ncbi.nlm.nih.gov/pubmed/7563328
93.Vazina, A., et al. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol, 2004. 171: 1830.
https://www.ncbi.nlm.nih.gov/pubmed/15076287
94.Galsky, M.D., et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer, 2021. 9.
https://www.ncbi.nlm.nih.gov/pubmed/34266883
95.Shukla, C.J., et al. Palliation of male genital cancers. Clin Oncol (R Coll Radiol), 2010. 22: 747.